The United States recommended a “pause” in the administration of Johnson & Johnson’s COVID-19 vaccine to investigate reports of potentially dangerous blood clots.
In a joint statement today, the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) said they were investigating clots in six women in the days after vaccination, in combination with lowered platelet counts.
The six cases were identified among 6.8 million doses of this vaccine administered in the United States. It involves six women, between the ages of 18 to 48 years. Symptoms occurred between six and 13 days after the vaccine was administered.
Federal distribution channels in the United States, including mass vaccination sites, will halt use of the injection, and states and other providers are expected as well.
CDC’s Advisory Committee on Immunization Practices is meeting tomorrow to discuss the cases, and the FDA has also launched an investigation.
“Until the process is complete, we recommend a pause in the use of this vaccine as a precaution,” said Drs. Anne Schuchat, deputy director of the CDC, and Peter Marks, director of the FDA’s Center for Biological Evaluation and Research, in a joint statement.